Qilu：QLF4113 has initiated a Phase I clinical study
BMS：Mezigdomide has been formally accepted for review.
Fosun：PSD502 approved for marketing in China.
Zelgen：Gecacitinib Hydrochloride received marketing approval
Hengrui：Dalpiciclib was approved
BMS：SOTYKTU™Deucravacitinibapproved for marketing in China.
Daiichi Sankyo：Vanflyta®Quizartinib marketing application submitted
TUL：UBT251 has initiated a Phase III clinical trial.
MSD:WELIREG®Belzutifan was approved for marketing in the United States.
Tasly：TCM0012 approved for marketing in China.